<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627363</url>
  </required_header>
  <id_info>
    <org_study_id>GYEYJR-3</org_study_id>
    <nct_id>NCT04627363</nct_id>
  </id_info>
  <brief_title>HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama</brief_title>
  <official_title>HAIC Synchronously Combined With Bevacizumab and Toripalimab First-line for Advanced Hepatocellular Carcinama</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm clinical study to preliminarily observe and evaluate the&#xD;
      efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil&#xD;
      and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line&#xD;
      therapy for advanced HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin&#xD;
      was effective and safe for hepatocellular carcinoma. Bevacizumab, an angiogenesis Inhibitors&#xD;
      was effectively used for hepatocelluar carcinama (HCC) therapy. Toripalimab, an programmed&#xD;
      cell death protein-1 (PD-1) antibody, was effective and tolerable in patients with&#xD;
      hepatocellular carcinoma and portal vein tumor thrombus. No study has evaluated HAIC plus&#xD;
      Bevacizumab and Toripalimab. Thus, the investigators carried out this prospective, single-arm&#xD;
      study to find out it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate at 6 months</measure>
    <time_frame>6 months]</time_frame>
    <description>Progression was defined as progressive disease by independent radiologic review according to mRECIST or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>OS is the length of time from the date of randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>ORR, as determined based on tumor response according to RECIST 1.1, is defined as the proportion of all randomized subjects whose best overall response (BOR) is either a CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Bevacizumab</condition>
  <condition>Liver Neoplasms</condition>
  <condition>Toripalimab</condition>
  <condition>Oxaliplatin</condition>
  <arm_group>
    <arm_group_label>HAIC plus Bevacizumab and Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic arterial infusion of oxaliplatin , fluorouracil, and leucovorin every 6 weeks. Lenvatinib 12 mg (or 8 mg) once daily (QD) oral dosing. Toripalimab, 240 mg intravenously every 3 weeks. Bevacizumab 15 mg/kg intravenously every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic arterial infusion chemotherapy</intervention_name>
    <description>administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 6 weeks</description>
    <arm_group_label>HAIC plus Bevacizumab and Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15mg/kg intravenously every 3 weeks</description>
    <arm_group_label>HAIC plus Bevacizumab and Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>240mg intravenously every 3 weeks</description>
    <arm_group_label>HAIC plus Bevacizumab and Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HCC diagnosed by histopathological examination or Guidelines for Diagnosis and&#xD;
             Treatment of Primary Liver Cancer or the recurrent HCC after surgery;&#xD;
&#xD;
          2. age between 18 and 75 years;&#xD;
&#xD;
          3. Stage B (middle stage) or C (late stage) HCC determined in accordance with Barcelona&#xD;
             Clinic Liver Cancer staging system (BCLC stage). In case of stage B.&#xD;
&#xD;
          4. No previous use of any systemic therapy or recurrent HCC.&#xD;
&#xD;
          5. Child-Pugh class A or B;&#xD;
&#xD;
          6. Eastern Cooperative Group performance status (ECOG) score of 0-2;&#xD;
&#xD;
          7. Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤&#xD;
             5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or&#xD;
             PT/APTT within normal limits Absolute neutrophil count (ANC) &gt;1,500/mm3&#xD;
&#xD;
          8. Prothrombin time ≤18s or international normalized ratio &lt; 1.7.&#xD;
&#xD;
          9. Ability to understand the protocol and to agree to and sign a written informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cholangiocellular carcinoma (ICC);&#xD;
&#xD;
          2. Patients with cancer thrombus in the main trunk of portal vein (Vp4), or cancer&#xD;
             thrombus in inferior vena cava should be excluded;&#xD;
&#xD;
          3. Accepting ablation or surgery or other system therapy as firt line therapy after&#xD;
             diagnose for primary HCC, ablation or system therapy as first line therapy for&#xD;
             recurrent HCC.&#xD;
&#xD;
          4. Serious medical comorbidities.&#xD;
&#xD;
          5. Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or&#xD;
             hepatic encephalopathy&#xD;
&#xD;
          6. Known history of HIV&#xD;
&#xD;
          7. History of organ allograft&#xD;
&#xD;
          8. Known or suspected allergy to the investigational agents or any agent given in&#xD;
             association with this trial.&#xD;
&#xD;
          9. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
         10. Evidence of bleeding diathesis.&#xD;
&#xD;
         11. Patients with clinically significant gastrointestinal bleeding within 30 days prior to&#xD;
             study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Gao</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kangshun Zhu, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qunfnag Zhou, MD</last_name>
    <phone>86 19868000115</phone>
    <email>zhouqun988509@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei Gao, Professor</last_name>
    <email>gaof@sysucc.org.cn</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhou Qunfang</investigator_full_name>
    <investigator_title>Clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

